Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | USP5 | P45974 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773965 | 0.92 | EGLN1 (0.53) | EGLN1 | |
| SCHEMBL1773271 | 0.92 | EGLN1 (0.55) | EGLN1 | |
| SCHEMBL1772707 | 0.91 | EGLN1 (0.49) | EGLN1USP5 | |
| SCHEMBL1772335 | 0.90 | EGLN1 (0.59) | EGLN1 | |
| SCHEMBL1773667 | 0.90 | EGLN1 (0.54) | EGLN1NOTUM | |
| SCHEMBL1773007 | 0.89 | EGLN1 (0.54) | EGLN1 | |
| SCHEMBL1772698 | 0.89 | EGLN1 (0.50) | EGLN1USP5 | |
| SCHEMBL12602082 | 0.88 | EGLN1 (0.50) | EGLN1 | |
| SCHEMBL1772552 | 0.88 | EGLN1 (0.48) | EGLN1 | |
| Hydrochloric Acid SCHEMBL1773285 | 0.88 | EGLN1 (0.49) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | EGLN1 16/4885FFAR4 1739/4885NOTUM 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.